Abstract
Aim. To achieve extensive information (regional) in relation with the tuberculosis identified in current clinical practice in patients with inflammatory rheumatic diseases treated with biological agents. Patients and methods. Twenty seven rheumatologists from 11 Romanian medicale center agreed to participate voluntarily and provide required data on tuberculosis (TB) occurring between January 1999 and June 2011 in their patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthropathy (PsA) in relation with anti-TNFα agent. This observational research included 693 patients (RA n=492, SA n=137, AP n= 64). All patients were screen for latent Mycobacterium tuberculosis infection (LTBI) before they start anti-TNFα treatment. Chemoprophylaxis with isoniazid before anti-TNFα therapy is recommended if the diameter of tuberculin skin test reaction is more than 5 mm (before 2005 only if indurations was more than 10 mm). We recorded the demographic characteristics, and complex information about disease, treatment, tuberculosis diagnosis and the comorbidities. Incidence rate of TB are presented as events/1,000 person-years with associated 95% confidence interval [95%CI]. Results. Fifteen patients were diagnosed with TB, most (60%) were born in rural areas and 40% in areas with higher incidence (≥ 80%ooo) of TB. The incidence of TB was 1.65‰ (IC95% [11.54-34.63]). The extra pulmonary sites were present in 53.3% of the cases. Cultures were positive for Mycobacterium tuberculosis in 11 cases (73.3%). Suspicion of TB was confirmed histological in 6 cases (40%). The average duration of developing TB after initiation of TNF inhibitor was 23.26 months (range one month to 120 months). In 7/12 TB cases treated with IFX the incidence appeared in the first year of treatment. Any of known risk factors don’t have a significant influence in our cohort. Conclusions. The risk of reactivation of a latent TB during biologic therapy is greater in patients with rheumatic inflammatory diseases living in geographical areas with high endemicity of TB infection. Reduced compliance to chemoprophylaxis may be responsible for the occurrence of these cases.
Highlights
The TNFα is a pro-inflammatory cytokine produced by macrophages and it is the common ground for many rheumatologic diseases, amongst which rheumatoid arthritis (RA), psoriatic arthropathy (PsA) and ankylosing spondylitis (AS) are the most studied [1]
Tubach coordinated a retrospective study on patients with multiple inflammatory diseases included in the RATIO registry; they had in common the anti-TNFα treatment [2]
The aim of our study was to evaluate the rate of TB in patients with RA, AS and PsA receiving biological therapy with anti-TNFα agent in daily practice
Summary
The TNFα is a pro-inflammatory cytokine produced by macrophages and it is the common ground for many rheumatologic diseases, amongst which rheumatoid arthritis (RA), psoriatic arthropathy (PsA) and ankylosing spondylitis (AS) are the most studied [1]. There is few data in the literature referring to the occurrence of this specific infection in patients with different inflammatory rheumatic disorders that had the anti-TNFα therapy as an extra risk factor. Tubach coordinated a retrospective study on patients with multiple inflammatory diseases included in the RATIO registry; they had in common the anti-TNFα treatment [2]. Amongst the EULAR recommendations on the way the adverse reactions should be collected and reported, there is the importance of achieving extensive regional or local data, where national reporting is not possible [3]. In this way possible errors given by specific characteristics of the patients can be avoided
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
